ArticleLeukemia & lymphoma2015
Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma.
Article in Leukemia & lymphoma, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Bone progression in multiple myeloma: Benefit of zoledronic acid for patients achieving at least Very Good Partial Response and prognostic value of bone turnover markers.British journal of haematology · 2026Trial
- Bone-modifying therapy in multiple myeloma: a comprehensive review.Frontiers in oncology · 2026Review
- Treatment of myeloma bone disease: When, how often, and for how long?Journal of bone oncology · 2025Review
- Multiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic Options.Targeted oncology · 2025Review
- First-Line Combination with Proteasome Inhibitor-Based Treatment and Zoledronic Acid Is Effective in Reducing Later Fractures in Multiple Myeloma Irrespective of Multiple Myeloma Bone Disease at Diagnosis.Hematology reports · 2024Article
- Article
- Association between CTX-1 and Fibulin-1 Serum Levels with Pathogenesis of Multiple Myeloma Cancer.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Review
- Use of bisphosphonates in multiple myeloma patients in Denmark, 2005-2015.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- The effect of pamidronate delivery in bisphosphonate-naïve patients on neutrophil chemotaxis and oxidative burst.Scientific reports · 2020Article
- Multiple Myeloma Associated Bone Disease.Cancers · 2020Review
- The dormant cancer cell life cycle.Nature reviews. Cancer · 2020Review
- Tumor Cell Dormancy and Reactivation in Bone: Skeletal Biology and Therapeutic Opportunities.JBMR plus · 2019Review
- Prevention Of Skeletal Related Events In Multiple Myeloma: Focus On The RANK-L Pathway In The Treatment Of Multiple Myeloma.OncoTargets and therapy · 2019Article
- Use of Bisphosphonates in Elderly Patients With Newly Diagnosed Multiple Myeloma.Journal of the National Comprehensive Cancer Network : JNCCN · 2019Article
- Clinical relevance of PET/CT in patients with newly diagnosed multiple myeloma.International journal of clinical and experimental pathology · 2019Article
- Clinical characteristics and prognosis of multiple myeloma with bone-related extramedullary disease at diagnosis.Bioscience reports · 2018Article
- Bone-targeted agents in multiple myeloma.Hematology reports · 2018Article
- New agents in the Treatment of Myeloma Bone Disease.Calcified tissue international · 2018Review
- Statins Are Associated With Reduced Mortality in Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
Zoledronic acid and pamidronate are the two bisphosphonates approved in the United States to reduce multiple myeloma skeletal complications. Little prior evidence exists comparing survival outcomes between the two. We evaluated the incidence of skeletal-related events and overall survival in patients with myeloma treated with zoledronic acid versus pamidronate using a cohort of 1018 United States veterans. At a median follow-up of 26.9 months, patients receiving zoledronic acid had a 22% reduction in risk of death compared to pamidronate (hazard ratio 0.78; 95% confidence interval, 0.67-0.92). The benefit persisted after controlling for potential confounders. Adjusted Cox modeling with inverse probability weighting and propensity score matching supported these findings. Zoledronic acid was also associated with a 25% decrease in skeletal-related events. Zoledronic acid is associated with increased overall survival and decreased skeletal-related events compared to pamidronate in patients with multiple myeloma and should become the preferred bisphosphonate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.